Atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) have vasodepressor effects, while in the kidney they have potent natriuretic and diuretic activities. Although ANF and BNP have similar biological activities, there are distinct features associated with each hormone. Differences include tissue distribution, susceptibility to degradation by endopeptidase, circulating plasma half-life, affinity for biological and clearance receptors, form of the peptide stored in secretory granules, and possible DNA regulatory sequences involved in gene expression. In adult hearts, the gene for ANF is preferentially expressed in the atria, and ventricular expression is less than 5% of that of the whole heart. In contrast, ventricular BNP mRNA represents greater than 70% of whole heart levels. ANF and BNP mRNA levels are augmented in the ventricle subsequent to a number of different pathophysiological conditions of volume and pressure overload, including hypertension and heart failure. Given that the BNP gene is expressed primarily in the ventricles and that the ratio of BNP to ANF is different in atria and ventricles, we hypothesize that there are clear differences in the regulation of synthesis of ANF and BNP. The objective of this proposal is to define transcriptional and post- transcriptional mechanisms involved in the differential regulation of the genes encoding ANF and BNP in pathophysiological conditions resulting in cardiac hypertrophy. To do this, we will make use of a new model of cardiac hypertrophy, utilizing cultured adult feline cardiocytes stimulated to beat with isoproterenol. Specifically, the hypotheses to be tested are: 1) that there are differences in the rates of transcription of the ANF and BNP genes, and furthermore that there are cis-acting regulatory elements in the 5' flanking sequences (FS) of the BNP gene which are distinct from those characterized for the ANF gene in neonatal cardiocytes; 2) that during cardiac hypertrophy reexpression of the ANF and BNP genes involves cis-acting regulatory regions distinct from those involved in normal tissue-specific expression of the genes; 3) that there are different trans- acting regulatory proteins affecting ANF and BNP gene expression in quiescent vs beating adult feline cardiocytes (a model of hypertrophic growth); and 4) that there are differences in the stabilities of ANF and BNP mRNAs in normal and hypertrophied ventricles. Thus, these studies will provide a detailed analysis of the differences in regulation of the ANF and BNP genes, and provide a basis for understanding the relevance of each hormone in disease states, such as hypertension and hypertrophy.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL028982-19
Application #
6349165
Study Section
Project Start
2000-09-01
Project End
2001-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
19
Fiscal Year
2000
Total Cost
$192,093
Indirect Cost
Name
Henry Ford Health System
Department
Type
DUNS #
073134603
City
Detroit
State
MI
Country
United States
Zip Code
48202
Kumar, Nitin; Liao, Tang-Dong; Romero, Cesar A et al. (2018) Thymosin ?4 Deficiency Exacerbates Renal and Cardiac Injury in Angiotensin-II-Induced Hypertension. Hypertension 71:1133-1142
Bryson, Timothy D; Gu, Xiaosong; Khalil, Remonda M et al. (2018) Overexpression of prostaglandin E2 EP4 receptor improves cardiac function after myocardial infarction. J Mol Cell Cardiol 118:1-12
Cerniello, Flavia M; Carretero, Oscar A; Longo Carbajosa, Nadia A et al. (2017) MAS1 Receptor Trafficking Involves ERK1/2 Activation Through a ?-Arrestin2-Dependent Pathway. Hypertension 70:982-989
Ramseyer, Vanesa D; Ortiz, Pablo A; Carretero, Oscar A et al. (2016) Angiotensin II-mediated hypertension impairs nitric oxide-induced NKCC2 inhibition in thick ascending limbs. Am J Physiol Renal Physiol 310:F748-F754
González, Germán E; Rhaleb, N-E; D'Ambrosio, Martin A et al. (2016) Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 311:H1287-H1296
Gu, Xiaosong; Xu, Jiang; Zhu, Liping et al. (2016) Prostaglandin E2 Reduces Cardiac Contractility via EP3 Receptor. Circ Heart Fail 9:
Kumar, Nitin; Nakagawa, Pablo; Janic, Branislava et al. (2016) The anti-inflammatory peptide Ac-SDKP is released from thymosin-?4 by renal meprin-? and prolyl oligopeptidase. Am J Physiol Renal Physiol 310:F1026-34
Zhu, Liping; Yang, Xiao-Ping; Janic, Branislava et al. (2016) Ac-SDKP suppresses TNF-?-induced ICAM-1 expression in endothelial cells via inhibition of I?B kinase and NF-?B activation. Am J Physiol Heart Circ Physiol 310:H1176-83
Saez, Fara; Hong, Nancy J; Garvin, Jeffrey L (2016) Luminal flow induces NADPH oxidase 4 translocation to the nuclei of thick ascending limbs. Physiol Rep 4:
Cerrato, Bruno D; Carretero, Oscar A; Janic, Brana et al. (2016) Heteromerization Between the Bradykinin B2 Receptor and the Angiotensin-(1-7) Mas Receptor: Functional Consequences. Hypertension 68:1039-48

Showing the most recent 10 out of 381 publications